Mendus
8.32 SEK -1.65%64 investors are following this company
Mendus develops cancer immunotherapies with a focus on the prevention of tumor recurrence, the leading cause of cancer-related deaths globally. Indications include acute myeloid leukemia, ovarian cancer and soft tissue sarcomas. The company previously went by the name Immunicum and was renamed Mendus following the merger with the Dutch private company DCprime in 2021. Mendus today has its headquarters in Stockholm and its operational activities in Leiden, The Netherlands.
P/E (24e)
-3.26
EV/EBIT (adj.) (24e)
-2.72
P/B (24e)
0.64
Dividend yield-% (24e)
-
Target price
14.00 SEK
Recommendation
Buy
Updated
18.6.2024
NASDAQ Stockholm
IMMU
Daily low / high price
8.13 / 8.61
SEK
Market cap
418.99M SEK
Turnover
298.65K SEK
Volume
36K
Business risk
Valuation risk
Current
Previous
Extensive report
Inderes' extensive report is an investor's handbook on customer companies covered by our research.
The latest extensive report was released
Read the reportAnalyst
![Antti Siltanen Antti Siltanen](https://www.inderes.se/cdn-cgi/image/format=auto,width=128,height=128,quality=90,fit=cover/https://core.inderes.fi/sites/default/files/2023-08/Antti_Siltanen.jpg)
Antti Siltanen
Analyst
Latest videos
Financial calendar
Interim report
2024-08-23
Interim report
2024-11-08
Annual report
2025-02-13
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Adrianus Van Herk | 35.7 % | 35.7 % |
Flerie Invest AB | 23.9 % | 23.9 % |
Premium
This content is for our Premium customers only.
Forum updates
Fint med många insynsköp senaste tiden. Får vi någon riktkurs från Inderes tro?
2/23/2024, 10:50 AM💙 4
Income statement
2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e | 2027e | |
---|---|---|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
growth-% | 150.0 % | -60.0 % | 150.0 % | |||||
EBITDA | -86.9 | -132.0 | -138.5 | -133.2 | -127.3 | -123.0 | -93.0 | -95.3 |
EBIT (adj.) | -86.0 | -130.1 | -133.7 | -125.9 | -127.3 | -123.0 | -93.0 | -95.3 |
EBIT | -86.0 | -130.1 | -133.7 | -125.9 | -127.3 | -123.0 | -93.0 | -95.3 |
Profit before taxes | -89.2 | -133.4 | -138.8 | -126.9 | -128.5 | -126.0 | -96.0 | -98.3 |
Net income | -89.2 | -133.4 | -138.8 | -126.9 | -128.5 | -126.0 | -96.0 | -98.3 |
EPS (adj.) | -10.74 | -13.38 | -13.92 | -3.04 | -2.55 | -2.50 | -1.91 | -1.95 |
growth-% | ||||||||
Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Dividend ratio |
Profitability and return on capital
2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e | 2027e | |
---|---|---|---|---|---|---|---|---|
EBITDA-% | -869,130.0 % | -3,298,775.0 % | -1,385,420.0 % | -1,332,210.0 % | -1,272,660.0 % | -1,229,630.0 % | -930,072.0 % | -952,637.0 % |
EBIT-% (adj.) | -860,270.0 % | -3,252,500.0 % | -1,336,940.0 % | -1,259,210.0 % | -1,272,660.0 % | -1,229,630.0 % | -930,072.0 % | -952,637.0 % |
EBIT-% | -860,270.0 % | -3,252,500.0 % | -1,336,940.0 % | -1,259,210.0 % | -1,272,660.0 % | -1,229,630.0 % | -930,072.0 % | -952,637.0 % |
ROE | -27.2 % | -20.2 % | -23.7 % | -20.8 % | -18.9 % | -21.4 % | -20.1 % | -25.8 % |
ROI | -25.3 % | -19.4 % | -22.3 % | -20.2 % | -18.7 % | -19.7 % | -15.8 % | -16.2 % |
Valuation
2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e | 2027e | |
---|---|---|---|---|---|---|---|---|
Share price (SEK) | 136.32 | 78.94 | 44.40 | 10.46 | 8.32 | 8.32 | 8.32 | 8.32 |
Shares | 8.3 | 10.0 | 10.0 | 41.8 | 50.4 | 50.4 | 50.4 | 50.4 |
Market cap | 1,132.6 | 787.0 | 442.6 | 437.3 | 419.0 | 419.0 | 419.0 | 419.0 |
Enterprise value | 988.2 | 631.7 | 430.0 | 316.5 | 346.5 | 472.5 | 568.5 | 666.8 |
EV/S | 98,818.6 | 157,924.0 | 42,998.0 | 31,653.6 | 34,652.8 | 47,249.2 | 56,849.9 | 66,676.3 |
EV/EBITDA | - | - | - | - | - | - | - | - |
EV/EBIT (adj.) | - | - | - | - | - | - | - | - |
EV/EBIT | - | - | - | - | - | - | - | - |
P/E (adj.) | - | - | - | - | - | - | - | - |
P/E | - | - | - | - | - | - | - | - |
P/B | 1.7 | 1.2 | 0.9 | 0.6 | 0.6 | 0.8 | 1.0 | 1.3 |
P/S | 113,258.6 | 196,749.0 | 44,263.0 | 43,730.5 | 41,899.2 | 41,899.2 | 41,899.2 | 41,899.2 |
Dividend yield | ||||||||
Equity ratio | 90.7 % | 91.1 % | 82.9 % | 93.2 % | 91.6 % | 82.0 % | 67.0 % | 51.7 % |
Gearing ratio | -21.8 % | -23.6 % | -2.5 % | -17.1 % | -11.1 % | 10.2 % | 34.8 % | 74.6 % |
Quarter data
Q1/23 | Q2/23 | Q3/23 | Q4/23 | 2023 | Q1/24e | Q2/24e | Q3/24e | Q4/24e | |
---|---|---|---|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | ||||||
EBITDA | -31.2 | -30.2 | -29.0 | -42.7 | -133.2 | -35.3 | -31.1 | -30.4 | -30.5 |
EBIT | -29.6 | -27.7 | -25.9 | -42.7 | -125.9 | -35.3 | -31.1 | -30.4 | -30.5 |
Profit before taxes | -30.2 | -3.3 | -52.2 | -41.2 | -126.9 | -35.6 | -31.4 | -30.7 | -30.8 |
Net income | -30.2 | -3.3 | -52.2 | -41.2 | -126.9 | -35.6 | -31.4 | -30.7 | -30.8 |
ShowingAll content types
Ändring av antalet aktier och röster i Mendus AB (publ)
Mendus: Vididencel-induced anti-tumor immune responses in ovarian cancer
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
ALISON trial data presented at ESMO Gynaecological Cancers demonstrate tumor-directed immune responses in the majority of patients treated with vididencel
Data från ALISON-studien presenterade vid ESMO Gynaecological Cancers visar på tumörriktade immunsvar hos majoriteten av patienterna som behandlats med vididencel
Mendus presented data on immune responses following vididencel administration
Mendus data presented at EHA substantiate the potential of vididencel to induce functional, clinically relevant immune responses in AML
Mendus presenterade data vid EHA som styrker vididencels potential att framkalla funktionella och kliniskt relevanta immunsvar vid AML
Mendus to participate in upcoming industry conferences
Mendus medverkar på kommande branschkonferenser
Reverse share split in Mendus AB (publ)
Sammanläggning av aktier i Mendus AB (publ)
![AML development on track](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=cover/https://content.inderes.se/assets/93456b63-8e1d-43a4-97f2-ba5211131ac8.png)
AML development on track
![Mendus Q1’24: Progress with main partnerships](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=cover/https://content.inderes.se/assets/837881da-c61f-425b-b427-2ced3c349abb.png)
Mendus Q1’24: Progress with main partnerships
Redeye: Mendus Q1 2024 - Funded until next major catalyst
![Mendus, Audiocast with teleconference, Q1, 2024](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=cover/https://content.inderes.se/assets/31364fc7-b3bb-45b2-b2c5-47db9aa8024b.png)